Is Lilly planning two brands for tirzepatide? CFO discusses diabetes and obesity possibilities
Eli Lilly is addressing the possibility of two brand names for tirzepatide — again. The drug — which is already approved to treat type 2 diabetes as Mounjaro — could be getting a different brand name when, as anticipated, it gets approved for an obesity indication.
That’s a definite maybe or maybe not, in light of CFO Anat Ashkenazi’s remarks at the Morgan Stanley healthcare conference on Tuesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.